The role of DDB2 downregulation in patients’ worse outcomes may be due to its role in suppressing epithelial-to-mesenchymal transition (EMT) [65,66], which is a process involved in metastasis and chemoresistance of cancer cells [67] (Figure 8). Here, DDB2 is linked to cancer.